华润医药(03320.HK) 宣布，集团旗下华润生物医药申报的“生物医药创新抗体药物研发”，入选国务院国资委发布的首批40项中央企业人工智能战略性高价值场景，标志着集团在人工智能与生物医药领域融合创新的探索与实践获得高度认可。
“生物医药创新抗体药物研发”场景深度融合了人工智能技术与抗体药物研发流程，针对传统抗体药物研发周期长、成本高、成功率低等痛点问题，借助人工智能强大的数据处理和分析能力，对抗体的结构设计、活性预测、亲和力优化等环节进行精准模拟与筛选，极大提升了研发效率，有望加速创新抗体药物的上市进程。
近年来，集团始终将科技创新视为驱动产业升级的核心引擎，未来将不断加大在人工智能技术与生物医药研发融合领域的投入，积极开展技术创新与应用拓展，利用AI+CADD技术提高药物发现的效率，降低研发成本，加速药物进入临床的过程。(su/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-08-19 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.